Telos Biotech

Website

Telos Biotech Inc.

4 Investors
Cell and Gene Therapy Manufacturing
Dallas, TX

Telos Biotech is a biotechnology startup that develops technologies to enhance the manufacturing of cell therapies. The company, launched by Cambrian Bio in 2022, focuses on addressing telomere shortening during cell expansion to improve the function, longevity, and robustness of therapeutic cells used to treat cancer and age-related diseases.

Products & Team

Telovance™

Biotech Platform TechnologySeed

Telovance™ is a proprietary protein complex delivered during the ex-vivo cell expansion phase of manufacturing. It works by rapidly and safely lengthening the shortest telomeres within the therapeutic cells, without the risks associated with constitutive telomerase expression.

Value Proposition

It solves the critical manufacturing challenge of telomere attrition, which occurs during the rapid cell expansion required to produce a therapeutic dose. This attrition limits the persistence and effectiveness of the final cell product, and Telovance™ overcomes this limitation.

Pain Points

Customers face significant limitations in cell therapy manufacturing, including loss of cell fitness, reduced proliferative capacity, and premature cellular aging (senescence) due to telomere shortening during necessary ex-vivo expansion.

Selectively targets and lengthens critically short telomeresImproves cellular lifespan, function, and therapeutic outcomesDesigned for seamless integration into multi-step cell engineering workflowsEnhances the fitness of various cell types, including CAR-T cells
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
Dallas, TX
Primary headquarters

Funding History

Total Raised:
$725.0K
E

Equity, Option to Acquire Offering

December 2025
$2.3M
Target
Progress
32%
Raised
$725.0K
Target
$2.3M
#000181570825000002